Loading…
Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro
In this communication, we report the synthesis and biological evaluation of beta -L-d4C and beta -L-Fd4C, which show exceptional potent activity against HBV and significant activity against HIV. Since patients receiving long-term, anti-HBV or -HIV nucleoside therapy have experienced delayed toxicity...
Saved in:
Published in: | Journal of medicinal chemistry 1996-04, Vol.39 (9), p.1757-1759 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a408t-a4b3da76388247c6fd5613b42a583b7e60f1371d42050e269414c3359a802aba3 |
---|---|
cites | cdi_FETCH-LOGICAL-a408t-a4b3da76388247c6fd5613b42a583b7e60f1371d42050e269414c3359a802aba3 |
container_end_page | 1759 |
container_issue | 9 |
container_start_page | 1757 |
container_title | Journal of medicinal chemistry |
container_volume | 39 |
creator | Lin, Tai-Shun Luo, Mei-Zhen Liu, Mao-Chin Zhu, Yong-Lian Gullen, Elizabeth Dutschman, Ginger E Cheng, Yung-Chi |
description | In this communication, we report the synthesis and biological evaluation of beta -L-d4C and beta -L-Fd4C, which show exceptional potent activity against HBV and significant activity against HIV. Since patients receiving long-term, anti-HBV or -HIV nucleoside therapy have experienced delayed toxicity, which may be linked to the drugs inhibition of mitochondrial DNA synthesis, the effect of beta -L-d4C and beta -L-Fd4C in decreasing the mitochondrial DNA content in cells upon long-term exposure to these two drugs was also studied. beta -L-d4C was also independently synthesized by Mansuri et al., however, no physical properties and spectroscopic data were reported. Furthermore, contrary to our results, they reported that this compound has no antiviral activity. |
doi_str_mv | 10.1021/jm950836q |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78014050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78014050</sourcerecordid><originalsourceid>FETCH-LOGICAL-a408t-a4b3da76388247c6fd5613b42a583b7e60f1371d42050e269414c3359a802aba3</originalsourceid><addsrcrecordid>eNqFks1uEzEQxxcEKqFw4AGQfICqlWrqj9315kjSlgRVUKmhV8vr9RKHXTu1vWr2xmPwHDwID8GT4CZRhPi8jDUzv_9fM_IkyTOMXmFE8MmiHWaooPnN_WSAM4JgWqD0QTJAiBBIckIfJY-9XyCEKCZ0L9krcsKyYT64d3KqvP5ogDAVuOpNmMfUA1sD8v3zl2MaAzzVlbKrHv5UqmJp3lfOwm9fYQNlH3SljQKH67RKx0drw989_mqRQVA3nXX2F6_zO7NjMLu14Gwl1TJoa0TT9ODSBmUCmJq5LnWwbj30pGuFARO1FEGHuMcIXGvXeXA4GV1vRvqHbNq2nbGVqrXUysh-p51GrTYxDc4-SR7WovHq6fbdTz6cn83GE3jx_s10_PoCihQVIcaSVoLltChIymReV1mOaZkSkRW0ZCpHNaYMVylBGVIkH6Y4lZRmQ1EgIkpB95ODje_S2ZtO-cBb7aVqGmGU7TxnBcJp1P4XxAzlhJAigkcbUDrrvVM1XzrdCtdzjPjdFfHdFUX2-da0K1tV7cjt2cT-i21feCma2gkjtd9hFDGGMYsY3GDaB7XatYX7xHNGWcZnl1d89I5M8Fs84lnkX254IT1f2M7Fr_Z_GO8H6yvxqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17062228</pqid></control><display><type>article</type><title>Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)</source><creator>Lin, Tai-Shun ; Luo, Mei-Zhen ; Liu, Mao-Chin ; Zhu, Yong-Lian ; Gullen, Elizabeth ; Dutschman, Ginger E ; Cheng, Yung-Chi</creator><creatorcontrib>Lin, Tai-Shun ; Luo, Mei-Zhen ; Liu, Mao-Chin ; Zhu, Yong-Lian ; Gullen, Elizabeth ; Dutschman, Ginger E ; Cheng, Yung-Chi</creatorcontrib><description>In this communication, we report the synthesis and biological evaluation of beta -L-d4C and beta -L-Fd4C, which show exceptional potent activity against HBV and significant activity against HIV. Since patients receiving long-term, anti-HBV or -HIV nucleoside therapy have experienced delayed toxicity, which may be linked to the drugs inhibition of mitochondrial DNA synthesis, the effect of beta -L-d4C and beta -L-Fd4C in decreasing the mitochondrial DNA content in cells upon long-term exposure to these two drugs was also studied. beta -L-d4C was also independently synthesized by Mansuri et al., however, no physical properties and spectroscopic data were reported. Furthermore, contrary to our results, they reported that this compound has no antiviral activity.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm950836q</identifier><identifier>PMID: 8627596</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - chemical synthesis ; Antiviral Agents - pharmacology ; Biological and medical sciences ; Drug Design ; hepatitis B virus ; Hepatitis B virus - drug effects ; HIV - drug effects ; human immunodeficiency virus ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Zalcitabine - analogs & derivatives ; Zalcitabine - chemical synthesis ; Zalcitabine - pharmacology</subject><ispartof>Journal of medicinal chemistry, 1996-04, Vol.39 (9), p.1757-1759</ispartof><rights>Copyright © 1996 American Chemical Society</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a408t-a4b3da76388247c6fd5613b42a583b7e60f1371d42050e269414c3359a802aba3</citedby><cites>FETCH-LOGICAL-a408t-a4b3da76388247c6fd5613b42a583b7e60f1371d42050e269414c3359a802aba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3077117$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8627596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Tai-Shun</creatorcontrib><creatorcontrib>Luo, Mei-Zhen</creatorcontrib><creatorcontrib>Liu, Mao-Chin</creatorcontrib><creatorcontrib>Zhu, Yong-Lian</creatorcontrib><creatorcontrib>Gullen, Elizabeth</creatorcontrib><creatorcontrib>Dutschman, Ginger E</creatorcontrib><creatorcontrib>Cheng, Yung-Chi</creatorcontrib><title>Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>In this communication, we report the synthesis and biological evaluation of beta -L-d4C and beta -L-Fd4C, which show exceptional potent activity against HBV and significant activity against HIV. Since patients receiving long-term, anti-HBV or -HIV nucleoside therapy have experienced delayed toxicity, which may be linked to the drugs inhibition of mitochondrial DNA synthesis, the effect of beta -L-d4C and beta -L-Fd4C in decreasing the mitochondrial DNA content in cells upon long-term exposure to these two drugs was also studied. beta -L-d4C was also independently synthesized by Mansuri et al., however, no physical properties and spectroscopic data were reported. Furthermore, contrary to our results, they reported that this compound has no antiviral activity.</description><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - chemical synthesis</subject><subject>Antiviral Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Drug Design</subject><subject>hepatitis B virus</subject><subject>Hepatitis B virus - drug effects</subject><subject>HIV - drug effects</subject><subject>human immunodeficiency virus</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Zalcitabine - analogs & derivatives</subject><subject>Zalcitabine - chemical synthesis</subject><subject>Zalcitabine - pharmacology</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNqFks1uEzEQxxcEKqFw4AGQfICqlWrqj9315kjSlgRVUKmhV8vr9RKHXTu1vWr2xmPwHDwID8GT4CZRhPi8jDUzv_9fM_IkyTOMXmFE8MmiHWaooPnN_WSAM4JgWqD0QTJAiBBIckIfJY-9XyCEKCZ0L9krcsKyYT64d3KqvP5ogDAVuOpNmMfUA1sD8v3zl2MaAzzVlbKrHv5UqmJp3lfOwm9fYQNlH3SljQKH67RKx0drw989_mqRQVA3nXX2F6_zO7NjMLu14Gwl1TJoa0TT9ODSBmUCmJq5LnWwbj30pGuFARO1FEGHuMcIXGvXeXA4GV1vRvqHbNq2nbGVqrXUysh-p51GrTYxDc4-SR7WovHq6fbdTz6cn83GE3jx_s10_PoCihQVIcaSVoLltChIymReV1mOaZkSkRW0ZCpHNaYMVylBGVIkH6Y4lZRmQ1EgIkpB95ODje_S2ZtO-cBb7aVqGmGU7TxnBcJp1P4XxAzlhJAigkcbUDrrvVM1XzrdCtdzjPjdFfHdFUX2-da0K1tV7cjt2cT-i21feCma2gkjtd9hFDGGMYsY3GDaB7XatYX7xHNGWcZnl1d89I5M8Fs84lnkX254IT1f2M7Fr_Z_GO8H6yvxqw</recordid><startdate>19960426</startdate><enddate>19960426</enddate><creator>Lin, Tai-Shun</creator><creator>Luo, Mei-Zhen</creator><creator>Liu, Mao-Chin</creator><creator>Zhu, Yong-Lian</creator><creator>Gullen, Elizabeth</creator><creator>Dutschman, Ginger E</creator><creator>Cheng, Yung-Chi</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19960426</creationdate><title>Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro</title><author>Lin, Tai-Shun ; Luo, Mei-Zhen ; Liu, Mao-Chin ; Zhu, Yong-Lian ; Gullen, Elizabeth ; Dutschman, Ginger E ; Cheng, Yung-Chi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a408t-a4b3da76388247c6fd5613b42a583b7e60f1371d42050e269414c3359a802aba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - chemical synthesis</topic><topic>Antiviral Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Drug Design</topic><topic>hepatitis B virus</topic><topic>Hepatitis B virus - drug effects</topic><topic>HIV - drug effects</topic><topic>human immunodeficiency virus</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Zalcitabine - analogs & derivatives</topic><topic>Zalcitabine - chemical synthesis</topic><topic>Zalcitabine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Tai-Shun</creatorcontrib><creatorcontrib>Luo, Mei-Zhen</creatorcontrib><creatorcontrib>Liu, Mao-Chin</creatorcontrib><creatorcontrib>Zhu, Yong-Lian</creatorcontrib><creatorcontrib>Gullen, Elizabeth</creatorcontrib><creatorcontrib>Dutschman, Ginger E</creatorcontrib><creatorcontrib>Cheng, Yung-Chi</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Tai-Shun</au><au>Luo, Mei-Zhen</au><au>Liu, Mao-Chin</au><au>Zhu, Yong-Lian</au><au>Gullen, Elizabeth</au><au>Dutschman, Ginger E</au><au>Cheng, Yung-Chi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1996-04-26</date><risdate>1996</risdate><volume>39</volume><issue>9</issue><spage>1757</spage><epage>1759</epage><pages>1757-1759</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>In this communication, we report the synthesis and biological evaluation of beta -L-d4C and beta -L-Fd4C, which show exceptional potent activity against HBV and significant activity against HIV. Since patients receiving long-term, anti-HBV or -HIV nucleoside therapy have experienced delayed toxicity, which may be linked to the drugs inhibition of mitochondrial DNA synthesis, the effect of beta -L-d4C and beta -L-Fd4C in decreasing the mitochondrial DNA content in cells upon long-term exposure to these two drugs was also studied. beta -L-d4C was also independently synthesized by Mansuri et al., however, no physical properties and spectroscopic data were reported. Furthermore, contrary to our results, they reported that this compound has no antiviral activity.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>8627596</pmid><doi>10.1021/jm950836q</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 1996-04, Vol.39 (9), p.1757-1759 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_78014050 |
source | American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list) |
subjects | AIDS/HIV Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - chemical synthesis Antiviral Agents - pharmacology Biological and medical sciences Drug Design hepatitis B virus Hepatitis B virus - drug effects HIV - drug effects human immunodeficiency virus Humans Medical sciences Pharmacology. Drug treatments Zalcitabine - analogs & derivatives Zalcitabine - chemical synthesis Zalcitabine - pharmacology |
title | Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T02%3A50%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20and%20Synthesis%20of%202%E2%80%98,3%E2%80%98-Dideoxy-%202%E2%80%98,3%E2%80%98-didehydro-%CE%B2-l-cytidine%20(%CE%B2-l-d4C)%20and%202%E2%80%98,3%E2%80%98-Dideoxy-2%E2%80%98,3%E2%80%98-didehydro-%CE%B2-l-5-%20fluorocytidine%20(%CE%B2-l-Fd4C),%20Two%20Exceptionally%20Potent%20Inhibitors%20of%20Human%20Hepatitis%20B%20Virus%20(HBV)%20and%20Potent%20Inhibitors%20of%20Human%20Immunodeficiency%20Virus%20(HIV)%20in%20Vitro&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Lin,%20Tai-Shun&rft.date=1996-04-26&rft.volume=39&rft.issue=9&rft.spage=1757&rft.epage=1759&rft.pages=1757-1759&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm950836q&rft_dat=%3Cproquest_cross%3E78014050%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a408t-a4b3da76388247c6fd5613b42a583b7e60f1371d42050e269414c3359a802aba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17062228&rft_id=info:pmid/8627596&rfr_iscdi=true |